SPG(600529) 东兴证券·2024-08-27 07:03Investment Rating - The report maintains a "Strong Buy" rating for Shandong Pharmaceutical Glass [1][3] Core Views - The company has optimized its product structure, leading to a profit growth rate that significantly exceeds revenue growth. The increase in profit is attributed to the strong sales of high-margin products like borosilicate molded bottles, despite a decline in revenue from non-core paper packaging products [2][3] - The company's gross margin improved to 32.35%, an increase of 5.43 percentage points year-on-year, driven by lower raw material prices and product structure optimization [2] - As the largest pharmaceutical packaging manufacturer in China, the company is expanding its production capacity, particularly for borosilicate molded bottles, which enhances its scale and cost advantages [2][3] Financial Summary - For the first half of 2024, the company achieved a revenue of 2.586 billion yuan, a year-on-year increase of 6.75%, and a net profit attributable to shareholders of 475 million yuan, up 23.26% year-on-year [1][2] - The company forecasts net profits of 1.021 billion yuan, 1.257 billion yuan, and 1.554 billion yuan for 2024, 2025, and 2026, respectively, with corresponding EPS of 1.54 yuan, 1.89 yuan, and 2.34 yuan [3][6] - The projected PE ratios for 2024, 2025, and 2026 are 14.1, 11.5, and 9.3 times, respectively, indicating a favorable valuation outlook [3][6]